Related Experiment Video
Updated: Jan 24, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Protection From Lethal Lassa Disease Can Be Achieved Both Before and After Virus Exposure by Administration of
Markus H Kainulainen1, Jessica R Spengler1, Stephen R Welch1
1Viral Special Pathogens Branch, Atlanta, Georgia.
Abstract:
Lassa fever is a frequently severe human disease that is endemic to several countries in West Africa. To date, no licensed vaccines are available to prevent Lassa virus (LASV) infection, even though Lassa fever is thought to be an important disease contributing to mortality and both acute and chronic morbidity. We have previously described a vaccine candidate composed of single-cycle LASV replicon particles (VRPs) and a stable cell line for their production. Here, we refine the genetic composition of the VRPs and demonstrate the ability to reproducibly purify them with high yields. Studies in the guinea pig model confirm efficacy of the vaccine candidate, demonstrate that single-cycle replication is necessary for complete protection by the VRP vaccine, and show that postexposure vaccination can confer protection from lethal outcome.
More Related Videos
10:11Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
Published on: September 27, 2014
10:16High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication
Published on: October 30, 2021
Related Concept Videos
What are Viruses?
Chromosome Replication
Lytic Cycle of Bacteriophages
Viral Replication: Lysogenic Cycle
Viral Replication: Lytic Cycle
Introduction to Virus